Paysign

Overview

Paysign is a publicly traded specialist affordability processor (NASDAQ: PAYS) used by pharma manufacturers for copay cards, PAP, foundation, and patient-affordability operations on top of its native payment-processing infrastructure. The company exited 2025 with 131 active patient-affordability programs, added 55 net programs during 2025, and grew pharma revenue by more than 167% year over year. The legacy “prepaid card” framing understates its current pharma footprint; the legacy plasma-donor and corporate payments businesses still exist alongside the pharma affordability lane.

Paysign is not a hub services platform, a broad commercialization vendor, or a specialty pharmacy. Manufacturers should evaluate it as a focused affordability and payment-rails partner that pairs with a hub, field reimbursement team, or patient-services vendor for the rest of the operating stack.

Affordability Capability Model

The framework below standardizes how Rx Almanac evaluates copay-financial-assistance capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Paysign is evaluated as a publicly traded specialist affordability processor used by pharma manufacturers for copay cards, PAP, foundation, and patient-affordability operations on top of its native payment-processing infrastructure.

Capability	Buyer should compare	Paysign readout
Copay card design and claims adjudication	Program setup, BIN/PCN/group logic, real-time pharmacy adjudication, benefit limits, reversals, and claims reconciliation.	Owned payment rails. Paysign operates its own payment-processing and adjudication infrastructure; 131 active patient-affordability programs at year-end 2025.
PAP, foundation, and free-drug support	Eligibility screening, income verification, foundation routing, free-drug workflows, renewals, and bridge program administration.	Affordability operations. Patient affordability is the primary growth lane; confirm PAP renewal logic, income verification, and bridge program scope in the SOW.
Accumulator, maximizer, and affordability controls	Detection and mitigation of accumulator/maximizer exposure, plan edits, alternative funding, and program rule tuning.	Confirm affordability operations in the RFP. Ask Paysign to describe specific accumulator/maximizer detection, alternative-funding response, and program-rule tuning workflows by brand.
Eligibility, enrollment, and patient communications	Digital enrollment, status updates, patient support, card activation, reminders, and multilingual service workflows.	Support-center capacity. September 2025 opened a 30,000 sq ft Henderson, NV patient service support center; quadrupled support capacity with bilingual 24/7 coverage for manufacturers, patients, and HCPs.
Payment rails, debit/card, and pharmacy integration	Card issuing, debit rails, reimbursement, pharmacy switch connectivity, payment settlement, and vendor integrations.	Payment infrastructure. Owned payment-processing platform underpins copay card adjudication, debit-card issuance, and pharmacy-switch settlement at scale.
Compliance, reporting, and GTN visibility	Program controls, audit trails, utilization reports, budget visibility, GTN impact, and manufacturer dashboards.	Confirm reporting layer in the RFP. Ask for sample manufacturer dashboards, reversal reporting, GTN-impact views, and audit-trail outputs at brand and payer level.

Buyer Fit

• Best buying context: Pharma manufacturers needing a vertically owned copay card, PAP, or foundation administrator backed by in-house payment rails rather than a hub services bundle.
• Best-fit buyers: Brands where out-of-pocket cost, PAP eligibility, accumulator/maximizer exposure, or pharmacy counter friction materially affect starts and adherence; programs that want a focused affordability counterparty separate from the hub.
• Less ideal fit: Manufacturers looking for end-to-end hub services, nursing, prior authorization at scale, or full commercialization support; Paysign is a specialist, not a one-stop hub.
• Commercial fit: Custom/RFP scoping; pricing is not publicly standardized, so define service levels, data feeds, launch timing, and governance in the statement of work.
• Contracting diligence: Pharmacy switch integration, accumulator/maximizer logic, PAP renewal workflows, data ownership, anti-kickback and state-law review responsibilities, and how Paysign coordinates with the manufacturer’s hub or field reimbursement team.

Differentiators

• Owned payment-processing platform: Paysign issues, adjudicates, and settles on its own infrastructure rather than routing through a third-party processor for the core copay-card transaction.
• Public-company disclosure layer: SEC filings and earnings calls give pharma diligence teams a public view of program counts, revenue mix, and operating capacity that most private affordability vendors do not provide.
• Scaled patient-service operations: The September 2025 Henderson, NV expansion quadrupled patient-service support capacity with bilingual 24/7 coverage.
• Cross-vertical scale: Plasma-donor payments, corporate payments, and pharma affordability all run on the same payment platform, which can support pharma manufacturers asking for cross-program reporting or shared payment rails.
• Pharma-revenue trajectory: 167%+ pharma revenue growth in 2025 and 55 net new programs in 2025 signal a vendor that is actively scaling the pharma lane rather than maintaining a legacy book.

RFP Questions

• How does Paysign detect accumulator, maximizer, and alternative-funding exposure before it erodes conversion, and what response workflows are included?
• Which pharmacy switch, adjudication, debit-card, and pharma-payment integrations are native to Paysign versus partner-delivered?
• What PAP, foundation, free-drug, and bridge program workflows are included, and how are eligibility and renewals handled?
• What budget, utilization, reversal, and GTN reporting can be delivered at brand and payer level, and at what cadence?
• How are anti-kickback, state-law, and PBM compliance reviews coordinated between Paysign and the manufacturer?
• How does Paysign coordinate with a separate hub, field reimbursement, or specialty pharmacy vendor on patient handoffs and data flows?
• Which named operating leads will own program implementation, launch surge staffing, and ongoing governance?

Recent Activity

• 2025-09: Opened a new 30,000 sq ft patient service support center in Henderson, NV; quadrupled support capacity with bilingual 24/7 coverage for manufacturers, patients, and HCPs.
• 2025-06: Single major commercial contract awarded covering 132 plasma center transitions from an incumbent provider, supporting trajectory to about 589 active plasma centers by Q1 2026.
• 2025-03: Acquired Gamma Innovation; Michael Ngo (former Gamma managing member) appointed Chief Innovation Officer post-deal.
• 2025: Patient affordability became the primary driver of growth and profitability per company commentary; pharma plus plasma forecast to reach revenue parity by end-2026.